Relating Spontaneously Reported Extrapyramidal Adverse Events to XXXX Rating Scales.

@entity1 @entity717 @entity1280 @entity161 @entity2146 @entity1767 @entity21
BACKGROUND: While antipsychotic-induced @entity21 ( @entity21 ) and @entity2146 remain important concerns in the treatment of @entity1 with @entity161 , the relationship between @entity717 rating scales and spontaneously reported @entity21 -related adverse events ( @entity21 -AEs) remains unexplored. METHODS: Data from four randomized, placebo- and @entity1767 -controlled @entity1280 trials were analyzed to examine the relationship between spontaneously reported @entity21 -AEs with the Simpson Angus Scale (SAS) and Barnes Akathisia Rating Scale (BARS). Categorical summaries were created for each treatment group to show the frequencies of subjects with @entity21 -AEs in each of the SAS and BARS categories at weeks 1, 3, and 6, and agreement between ratings was quantified by means of weighted kappa (k). RESULTS: In general, we found greater frequencies of @entity21 -AEs with increasing severity of the SAS and BARS scores. The @entity21 -AEs reported with a "none" SAS score ranged from 0 to 22.2%, with a "mild" SAS score from 3.3 to 29.0%, and with a "moderate" SAS score from 0 to 100%. No subjects in any treatment group reported "severe" SAS scores or corresponding @entity21 -AEs. Agreement between SAS scores and @entity21 -AEs was poor for @entity1280 and placebo (k < 0.2) and only slightly better for @entity1767 . The @entity21 -AEs reported with "non questionable" BARS scores ranged from 1.9 to 9.8%, with "mild moderate" BARS scores from 12.8 to 54.6%, and with "marked severe" scores from 0 to 100%. Agreement was modest for @entity1280 and placebo (k < 0.4) and moderate for @entity1767 (k < 0.6). CONCLUSIONS: These findings may reflect either underreporting of AEs by investigators and subjects or erroneous rating scale evaluations.
